1. Home
  2. BNRG vs GRI Comparison

BNRG vs GRI Comparison

Compare BNRG & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brenmiller Energy Ltd

BNRG

Brenmiller Energy Ltd

HOLD

Current Price

$1.83

Market Cap

1.9M

Sector

N/A

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.39

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNRG
GRI
Founded
2012
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9M
1.9M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
BNRG
GRI
Price
$1.83
$2.39
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$644.00
AVG Volume (30 Days)
146.5K
955.8K
Earning Date
02-27-2026
01-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$387,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
843.90
N/A
52 Week Low
$2.19
$2.19
52 Week High
$60.55
$311.36

Technical Indicators

Market Signals
Indicator
BNRG
GRI
Relative Strength Index (RSI) 48.46 54.39
Support Level $2.19 $2.21
Resistance Level $2.84 $2.53
Average True Range (ATR) 0.46 0.54
MACD -0.06 -0.08
Stochastic Oscillator 35.97 33.36

Price Performance

Historical Comparison
BNRG
GRI

About BNRG Brenmiller Energy Ltd

Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: